鲁索利替尼
医学
淋巴细胞白血病
诱导化疗
化疗
内科学
肿瘤科
费城染色体
癌症研究
白血病
染色体易位
骨髓
遗传学
生物
基因
骨髓纤维化
作者
Yangyang Ding,Julie W. Stern,Tracey F. Jubelirer,Gerald B. W. Wertheim,Fumin Lin,Fengqi Chang,Zhaohui Gu,Charles Grenfell Mullighan,Yong Li,Richard C. Harvey,I‐Ming Chen,Cheryl L. Willman,Stephen P. Hunger,Marilyn M. Li,Sarah Kathleen Tasian
出处
期刊:Haematologica
[Ferrata Storti Foundation]
日期:2018-05-17
卷期号:103 (9): e427-e431
被引量:70
标识
DOI:10.3324/haematol.2018.192088
摘要
Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failurePatients with Philadelphia chromosome-like B-cell lymphoblastic leukemia (Ph-like or BCR-ABL1-like B-ALL) experience high relapse rates and are difficult to cure with conventional chemotherapy.1,2 The Ph-like ALL subtype comprises 15-25% of B-ALL in older children and adolescents/young adults (AYAs) and 20-40% of cases in older adults.1,2 Ph-like ALL is driven by alterations in cytokine receptor signaling pathway genes that induce oncogenic kinase signaling, suggesting therapeutic potential for kinase inhibitors. 1 Approximately 50% of Ph-like ALL has rearrangements in CRLF2 (cytokine receptor-like factor 2), often with concomitant JAK2 or JAK1 point mutations, which leads to constitutive JAK/STAT signaling targetable by JAK inhibitors (JAKi) such as ruxolitinib.JAK2 and EPOR translocations comprise an additional 8-12% of Ph-like ALL in children/AYAs and adults.1-3JAK2-or EPOR-rearranged ALLs are also characterized by hyperactive JAK/STAT signaling and are potentially very sensitive to JAK inhibition.3,4 While JAKi addition to multi-agent chemotherapy is under current clinical investigation in children and adults with newlydiagnosed or relapsed CRLF2-R/JAK-mutant Ph-like ALL via early-phase trials (clinicaltrials.govidentifier 02723994, 03117751, 02420717), whether this therapeutic strategy
科研通智能强力驱动
Strongly Powered by AbleSci AI